At the annual general meeting in Chordate Medical Holding AB (publ) (“Chordate” or the “Company”) held on 15 May 2024, it was resolved to implement a consolidation of shares 1:500, meaning that five hundred (500) shares are combined into one (1) new share. The annual general meeting authorised the board of directors to determine the record date for the consolidation. The board of directors have, with support of the authorisation from the annual general meeting, decided that the record date shall be 30 August 2024.
The last day of trading in the Company’s shares before the consolidation is 28 August 2024 and the first day of trading in the Company’s shares after the consolidation is 29 August 2024. The Company’s share price will thus reflect the effect of the consolidation from 29 August 2024. The consolidation will be carried out automatically by Euroclear Sweden AB, and shareholders do not need to take any measures.
Through the consolidation, the total number of shares in the Company will decrease from 490,111,500 to 980,223.
As a result of the consolidation, the Company’s share will from 29 August 2024 change ISIN code. The new ISIN code for the Company’s share is SE0022726139.
The shareholders in the Company will automatically receive a new, lower, number of shares in proportion to their shareholdings at the record date. Those shareholders whose shareholding, on the record date, is not evenly divisible by five hundred (500) will receive shares free of charge for their shareholding to be evenly divisible by five hundred (500). The distribution of shares takes place through Euroclear Sweden AB without additional measures needed to be taken by shareholders.
For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Cell: +46 733-874277
About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com
The company’s Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.
N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.
